Houston data analytics firm acquired by Austin agency

m&a moves

Statistical Vision has been rebranded as Hahn Stats. Image via Getty Images

Statistical Vision, a Houston-based data and analytics firm, has been scooped up by Austin-based marketing and communications agency Hahn Public for an undisclosed amount.

The deal expands Hahn Public to a 48-person agency with combined annual revenue exceeding $10 million. Statistical Vision has been rebranded as Hahn Stats.

“Our clients come to us drowning in data — sales transactions, marketing information, commodity prices, import and export data, demographics, weather forecasts, etcetera,” Michael Griebe, co-founder and chief statistical officer of what now is Hahn Stats, says in a news release. “We build predictive analytic models to answer specific questions and to point our clients towards revenue growth.”

Griebe and Dirk Van Slyke founded Statistical Vision in 2014. The company's local office is at The Cannon West Houston. Hahn Stats LLC also has an office in Denver.

The data and analytics prowess developed by Statistical Vision will benefit Hahn Public clients like Houston-based ZTERS, Whataburger, the Texas Department of Agriculture, Beef-Loving Texans, H-E-B’s Central Market, Vital Farms, the Propane Education & Research Council, OneGas, GPA Midstream, the East Texas Electric Cooperative, and the Northeast Texas Regional Mobility Authority.

Jeff Hahn, principal of Hahn Public, says the acquisition of Statistical Vision and its data and analytics capabilities will help Hahn Public’s array of food and energy clients, who “continue to face a rapidly changing and uncertain landscape.”

Other businesses under the Hahn umbrella are Apron Food & Beverage Communications, Predictive Media Network, and White Lion Interactive.

Statistical Vision shares key data points it's watching as companies return to work amid the COVID-19 outbreak. Getty Images

Houston data startup analyzes COVID-19 risks as companies return to work

Guest column

In an effort to better help our clients, and frankly all of us, maneuver these uncertain times and to better understand what the upcoming months are likely to bring, we have applied our data science expertise to create a structural model of the spread of COVID-19. The aim of the national model is to determine specifically how mobility and weather impact the local transmission rates while controlling for population density, population immunity rate and the fact that people are taking more precautions.

When I discuss COVID19 with other Houstonians, I'm often asked "We're going back to work — there's traffic! Why haven't cases spiked?"

First, it is worth noting that cases and deaths have increased again in Harris County. But, the question is still valid. Greg Abbott started allowing things to open six weeks ago and we are only starting to see a rise now.

Fortunately, our model (being quantitative and multivariate) can explain why cases may not have 'spiked' the way that was expected. There are four main reasons why cases are only starting to tick up now:

  1. There has not been a 'spike' in people leaving their homes. While Greg Abbott did allow restaurants, movie theaters and malls to begin re-opening on April 30, there was not a sudden spike in people leaving their homes. Indeed, the "people staying home" index, according to Google Mobility Data, peaked on April 1 at 22 percent above normal and has gradually decreased ever since. In Harris County, the extent people are staying at home stands at 14 percent above normal as of May 29 (unfortunately, Google Mobility Data reports 7 to 10 days after the fact.) So, from the peak 'stay at home' measure, we were only a third the way back to normal last week.
  2. Temperatures have increased. Our model indicates that warmer temperatures decrease the transmission rate of COVID19. Our model does not posit a mechanism, but we can rule out both geographic explanations and behavioral explanations, which leaves us with the compelling reason to believe that temperatures matter.
  3. People's behaviors when they do go out have changed. These changes — everything from masks, to skipping hand shakes, to readily available hand sanitizer, to keeping your distance, to staying home when you're feeling sick — have an important and measurable impact on the spread.
  4. Kids are not back in school yet. While our model does not directly measure the impact of kids being in school, the estimate our model produces measuring the importance of staying at home (2.6) is higher than they should be (2, mathematically speaking). We suspect that's because we are missing an important cohort that started staying at home at the same time mobile phone users started staying at home - kids that don't have cell phones. So, while it may seem like we are most of the way back to normal, with regards to going out, being summer time in Houston, kids are not at school, which is likely keeping the rate of spread down.
All of that said, the gradual increase in people leaving their homes has had an impact. And now, cases and deaths are starting to increase. Our model reminds us that there are a variety of factors impacting the transmission rate. Right now, temperatures, people's behaviors and schools being out work in our favor. Come September, two of those three will turn the other way.
------
Michael Griebe is the co-founder and chief statistical officer at Houston-based Statistical Vision. To read more about the company's initiative, click here.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings